{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.7","upperLimit":"100.0","value":"99.8"},{"groupId":"OG001","lowerLimit":"99.2","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"448"}],"units":"Participants"}],"title":"Anti HPV 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.1","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"98.8","upperLimit":"100.0","value":"99.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"448"}],"units":"Participants"}],"title":"Anti HPV 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.2","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"448"}],"units":"Participants"}],"title":"Anti HPV 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.1","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"98.5","upperLimit":"99.9","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"471"}],"units":"Participants"}],"title":"Anti HPV 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"98.9","upperLimit":"100.0","value":"99.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"488"}],"units":"Participants"}],"title":"Anti HPV 31"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"98.9","upperLimit":"100.0","value":"99.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"493"}],"units":"Participants"}],"title":"Anti HPV 33"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.5","upperLimit":"99.9","value":"99.6"},{"groupId":"OG001","lowerLimit":"98.0","upperLimit":"99.8","value":"99.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"470"},{"groupId":"OG001","value":"515"}],"units":"Participants"}],"title":"Anti HPV 45"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"title":"Anti HPV 52"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"98.8","upperLimit":"100.0","value":"99.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"478"}],"units":"Participants"}],"title":"Anti HPV 58"}],"denoms":[{"counts":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"533"}],"units":"Participants"}],"description":"Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. The percentage of participants who were seronegative on Day 1 and have anti-HPV titer greater or equal to the type-specific serostatus cutoff at 4 weeks postdose 3 was assessed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Young adult women 16- to 26-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG000","title":"Women 16-26 Years of Age"},{"description":"Adult women 27- to 45-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG001","title":"Women 27-45 Years of Age"}],"paramType":"NUMBER","populationDescription":"Received all 3 vaccinations of the correct dose and within acceptable day ranges, had evaluable serology results at Day 1 and Month 7, must have been seronegative to the appropriate HPV type at Day 1 and had no protocol deviations that could interfere with the evaluation of participant's immune response to the 9vHPV vaccine.","reportingStatus":"POSTED","timeFrame":"4 weeks post vaccination 3 (Month 7)","title":"Percentage of Participants Who Seroconverted to Each of the Anti-HPV Types","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}